DELSOL Avocats advised Framatome, an international leader in nuclear energy, on its acquisition of a minority stake in the capital of Global Morpho Pharma, a French startup created in 2018 that develops innovative equipment and provides high value-added services to radiopharmaceutical companies for the production and distribution of medical radioisotopes.
This operation allows Framatome to strengthen its Framatome Healthcare brand and to reinforce its commitment to the fight against cancer.
Global Morpho Pharma will thus be able to accelerate the industrialisation of its technologies and strengthen its research and development efforts.
DELSOL Avocats advised Framatome with a team including :
Philippe Malikian, partner, et Alexia Demonchy, associate, on corporate matters ;
Stéphane Perrin, partner, et Emilie Sullo, associate, on intellectual property matters.